OXiGENE (OXGN) Narrows Loss in FY11; CFO Murphy's Tenure Expires
Tweet
Share
E-mailGet Alerts OXGN Hot Sheet
Price: $0.70 --0%
Financial Fact:
Research and development: 2.08M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Research and development: 2.08M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
OXiGENE, Inc. (Nasdaq: OXGN) reported a net loss of 86 cents per share for 2011, narrower than the $5.96 loss per share reported in the prior year.
OXiGENE also announced today that Jim Murphy's tenure as Chief Financial Officer will end at the end of March. Since the Company's restructuring in September 2011 and decision to consolidate its operations in South San Francisco, Murphy has served in this role as a consultant. Murphy will be succeeded by David Johnson, an experienced financial executive, who will assume the role of OXiGENE's principal financial executive and chief financial officer at the end of March.
OXiGENE also announced today that Jim Murphy's tenure as Chief Financial Officer will end at the end of March. Since the Company's restructuring in September 2011 and decision to consolidate its operations in South San Francisco, Murphy has served in this role as a consultant. Murphy will be succeeded by David Johnson, an experienced financial executive, who will assume the role of OXiGENE's principal financial executive and chief financial officer at the end of March.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
- AEye grants 125,000 RSUs to new chief revenue officer
- Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, Management ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
